Dr. Nikolai Tankovich, President Of Stemedica, Appointed Legate to The Center of Science and Society at The University of Oxford

Share Article

The Board of Trusties of the Centre for Science and Society at Trinity College of the University of Oxford, England has appointed Nikolai Tankovich, MD, PhD, FASLMS as a Legate of the Centre. Dr. Tankovich is President and Chief Medical officer of Stemedica Cell Technologies, Inc. and Chairman of Stemedica International S.A. a manufacturer of ischemic tolerant adult allogeneic stem cells.

Dr Nikolai Tankovich, President and Chief Medical Officer of Stemedica at the Centre for Science and Society at Trinity College, a constituent college of the University of Oxford, England

Dr Nikolai Tankovich, President and Chief Medical Officer of Stemedica at the Centre for Science and Society at Trinity College, a constituent college of the University of Oxford, England

We are honored that Dr. Tankovich will be an ambassador for the Centre to promote discussion of important issues connecting science and society.

The Board of Trusties of the Centre for Science and Society at Trinity College of the University of Oxford, England has appointed Nikolai Tankovich, MD, PhD, FASLMS as a Legate of the Centre. Dr. Tankovich is President and Chief Medical officer of Stemedica Cell Technologies, Inc. and Chairman of Stemedica International S.A. (http://www.stemedica.com) a manufacturer of ischemic tolerant adult allogeneic stem cells. Stemedica is headquartered in San Diego, California and Lausanne, Switzerland.

Dr. Tankovich has been a frequent lecturer and guest speaker at the Centre for the last several years. The position of Legate recognizes the importance of his continuing role in reporting on the latest worldwide trends in regenerative medicine and biotechnology. Dr Tankovich is a surgical oncologist who holds a Masters Degree in Physics and a PhD in Biophysics. He is a Fellow of the American Society of Laser Medicine and Surgery. Dr. Tankovich is the author of multiple patents in the fields of stem cells and laser science.

Dr. Frank C. Schuller, Director of the Centre for Science and Society at Trinity College said, “We are pleased to formalize our valued relationship with Dr. Tankovich by naming him a Legate of the Center. This honor is in recognition of his extensive contributions to advancing scientific understanding at the University of Oxford, and in anticipation of many years of continuing involvement.”

Speaking of his lecturing at Trinity College, Dr. Tankovich noted, “It is always a pleasure to present the latest medical and scientific information to some of the brightest researchers and scientists in the world. I look forward to working with The Center to explore the boundaries of science and technology to help translate research into meaningful cures for many of the presently chronic diseases and conditions that are prevalent today.”

Richard Silcock, Associate Director of the Centre, said, "During recent years, Dr. Tankovich has generously contributed his extensive knowledge and practical expertise to stimulate lively debates at the Centre on stem cell research and its medical or commercial applications. He joins a panel of Legates who have distinguished themselves in their careers. We are honored that Dr. Tankovich will be an ambassador for the Centre to promote discussion of important issues connecting science and society."

About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies Inc. (http://www.stemedica.com) is a specialty biopharmaceutical company that is committed to the development and manufacturing of best-in-class adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and human clinical trials. The Company is currently conducting clinical trials for stroke under US IND using ischemic tolerant mesenchymal (itMSC) stem cells. Regulatory pathways for spinal cord injury, diabetic retinopathy, acute myocardial infarct, acute respiratory distress syndrome and wound repair are also underway.

For more information regarding Stemedica Cell Technologies, Inc. contact Dave McGuigan at dmcguigan(at)stemedica(dot)com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dave McGuigan
Stemedica Cell Technologies Inc
(858) 658-0910
Email >
Visit website